National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable TA1195 30 September 2026 30 September 2026 Isatuximab with ...
National Institute for Health and Care Excellence

Prostate cancer

All NICE products on prostate cancer. Includes any guidance, advice and quality standards.
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy

Evidence-based recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-low metastatic or unresectable breast cancer after chemotherapy in adults. This guidance updates and replaces NICE ...
National Institute for Health and Care Excellence

Epilepsies: diagnosis and management

This guideline has been updated and replaced by epilepsies in children, young people and adults ...
National Institute for Health and Care Excellence

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

Evidence Documents containing the evidence that was used to develop the recommendations. Supporting evidence Surveillance report 2024 exceptional surveillance of familial breast cancer: classification ...
National Institute for Health and Care Excellence

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

This guidance has been updated and replaced by NICE technology appraisal guidance on pembrolizumab with pemetrexed and platinum chemotherapy for untreated ...
National Institute for Health and Care Excellence

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes

intermittently scanned continuous glucose monitoring. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following ...
National Institute for Health and Care Excellence

Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy

Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults. There is a commercial ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. Next review: More ...
National Institute for Health and Care Excellence

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure

Evidence-based recommendations on lusutrombopag (Mulpleo) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure. The scope for this multiple ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...